{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:04:20Z","timestamp":1747155860717,"version":"3.40.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish Government","award":["DEP2012-37494"],"award-info":[{"award-number":["DEP2012-37494"]}]},{"name":"Catholic University of Valencia","award":["2013-168-002","2012-011-001"],"award-info":[{"award-number":["2013-168-002","2012-011-001"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.atherosclerosis.2014.12.055","type":"journal-article","created":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T02:16:37Z","timestamp":1419992197000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-5084","authenticated-orcid":false,"given":"Rafael","family":"Alis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Sanchis-Gomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Risso-Ballester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carme","family":"Perez-Quilis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Cortell-Ballester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose R.","family":"Blesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/CIR.0b013e318282ab8f","article-title":"Executive summary: heart disease and stroke statistics\u20132013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2014.07.048","article-title":"Mechanism of action of anti-hypercholesterolemia drugs and their resistance","volume":"741c","author":"Tiwari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbalip.2005.03.006","article-title":"Modulation of regulatory factors involved in cholesterol metabolism in response to feeding of pravastatin- or cholesterol-supplemented diet in chickens","volume":"1734","author":"Matsuyama","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0005-2760(94)90200-3","article-title":"Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins","volume":"1212","author":"Grunler","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib5","doi-asserted-by":"crossref","first-page":"28110","DOI":"10.1074\/jbc.M001280200","article-title":"Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine","volume":"275","author":"Warner","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib6","first-page":"483","article-title":"Statins: a new insight into their mechanisms of action and consequent pleiotropic effects","volume":"59","author":"Jasinska","year":"2007","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib7","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2013.08.1626","article-title":"How do statins work?: changing paradigms with implications for statin allocation","volume":"62","author":"Blaha","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-0033-1343892","article-title":"Venous thrombosis associated with HMG-CoA reductase inhibitors","volume":"39","author":"Lippi","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/hrt.2008.152041","article-title":"Cardiovascular medication, physical activity and mortality: cross-sectional population study with ongoing mortality follow-up","volume":"95","author":"Stamatakis","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib10","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib11","doi-asserted-by":"crossref","first-page":"g3743","DOI":"10.1136\/bmj.g3743","article-title":"Non-cardiovascular effects associated with statins","volume":"349","author":"Desai","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib12","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2007.12.029","article-title":"The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg","volume":"200","author":"Kearns","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10557-013-6483-8","article-title":"Exercise-induced myalgia may limit the cardiovascular benefits of statins","volume":"27","author":"Opie","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1476-511X-11-40","article-title":"Statin therapy, myopathy and exercise\u2013a case report","volume":"11","author":"Semple","year":"2012","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib18","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s11606-008-0636-7","article-title":"Prevalence of musculoskeletal pain and statin use","volume":"23","author":"Buettner","year":"2008","journal-title":"J.\u00a0Gen. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/MOL.0b013e32833c1edf","article-title":"The effects of statins on skeletal muscle strength and exercise performance","volume":"21","author":"Krishnan","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ptj\/85.5.459","article-title":"Potential adverse effects of statins on muscle","volume":"85","author":"Tomlinson","year":"2005","journal-title":"Phys. Ther."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JES.0b013e31826c169e","article-title":"Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes","volume":"40","author":"Parker","year":"2012","journal-title":"Exerc. Sport Sci. Rev."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cjca.2011.05.007","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mus.21817","article-title":"Statin-associated myopathy and its exacerbation with exercise","volume":"42","author":"Meador","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.numecd.2012.04.012","article-title":"Discontinuation of statin therapy due to muscular side effects: a survey in real life","volume":"23","author":"Rosenbaum","year":"2013","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.atherosclerosis.2014.12.055_bib27","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.2337\/dcS13-2038","article-title":"Intolerance to statins: mechanisms and management","volume":"36","author":"Bitzur","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib28","article-title":"Allopurinol prevents cardiac and skeletal muscle damage in professional soccer players","author":"Sanchis-Gomar","year":"2014","journal-title":"Scand. J. Med. Sci. Sports"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib29","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/jama.289.19.2503-b","article-title":"Allopurinol and Markers of Muscle Damage Among Participants in the Tour de France","volume":"289","author":"G\u00f3mez-Cabrera","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12192-014-0543-2","article-title":"Effects of allopurinol on exercise-induced muscle damage: new therapeutic approaches?","volume":"20","author":"Sanchis-Gomar","year":"2015","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ijcard.2009.05.051","article-title":"Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure","volume":"145","author":"Tousoulis","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib32","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/MCB.21.11.3840-3852.2001","article-title":"Selective inhibition of selenocysteine tRNA maturation and selenoprotein synthesis in transgenic mice expressing isopentenyladenosine-deficient selenocysteine tRNA","volume":"21","author":"Moustafa","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/MCB.7.1.177","article-title":"Isolation and characterization of MOD5, a gene required for isopentenylation of cytoplasmic and mitochondrial tRNAs of Saccharomyces cerevisiae","volume":"7","author":"Dihanich","year":"1987","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1152\/physrev.00039.2013","article-title":"Selenoproteins: molecular pathways and physiological roles","volume":"94","author":"Labunskyy","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/hmg\/ddq515","article-title":"Satellite cell loss and impaired muscle regeneration in selenoprotein N deficiency","volume":"20","author":"Castets","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.toxlet.2012.10.010","article-title":"Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells","volume":"215","author":"Fuhrmeister","year":"2012","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib37","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40279-014-0224-4","article-title":"The effects of statin medications on aerobic exercise capacity and training adaptations","volume":"44","author":"Murlasits","year":"2014","journal-title":"Sports Med."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib39","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3164\/jcbn.40.194","article-title":"Protective effects of coenzyme q(10) on decreased oxidative stress resistance induced by simvastatin","volume":"40","author":"Kettawan","year":"2007","journal-title":"J.\u00a0Clin. Biochem. Nutr."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2013.04.009","article-title":"Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: implications for statin-induced rhabdomyolysis","volume":"711","author":"Vaughan","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1152\/japplphysiol.01362.2011","article-title":"Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance","volume":"113","author":"Muraki","year":"2012","journal-title":"J.\u00a0Appl. Physiol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/eurheartj\/ehr224","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1","volume":"33","author":"Bouitbir","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2012.12.023","article-title":"Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy","volume":"325","author":"Stringer","year":"2013","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib44","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0006-291X(82)80124-1","article-title":"Free radicals and tissue damage produced by exercise","volume":"107","author":"Davies","year":"1982","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF01003142","article-title":"The histochemical localization of xanthine oxidase","volume":"10","author":"Ibrahim","year":"1978","journal-title":"Histochem. J."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1748-1716.1988.tb08475.x","article-title":"Indication of in\u00a0vivo xanthine oxidase activity in human skeletal muscle during exercise","volume":"134","author":"Hellsten","year":"1988","journal-title":"Acta Physiol. Scand."},{"issue":"Pt 1","key":"10.1016\/j.atherosclerosis.2014.12.055_bib47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1113\/jphysiol.1997.sp021855","article-title":"Xanthine oxidase in human skeletal muscle following eccentric exercise: a role in inflammation","volume":"498","author":"Hellsten","year":"1997","journal-title":"J.\u00a0Physiol."},{"year":"2011","series-title":"Health, United States, 2010: with Special Feature on Death and Dying","author":"National Center for Health, S, Health, United States","key":"10.1016\/j.atherosclerosis.2014.12.055_bib48"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2125.2005.02478.x","article-title":"Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997\u20132003","volume":"60","author":"Walley","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib50","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib51","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib52","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1001\/jama.2013.281348","article-title":"Statin therapy for primary prevention of cardiovascular disease","volume":"310","author":"Taylor","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.12.055_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0091270012439715","article-title":"Clinical risk factors for adverse events in allopurinol users","volume":"53","author":"Ryu","year":"2013","journal-title":"J.\u00a0Clin. Pharmacol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014016773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014016773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T18:05:38Z","timestamp":1650909938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915014016773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0021915014016773"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.12.055","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.12.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}